688553 汇宇制药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-1.3188.3983.7336.84420.690
总资产报酬率 ROA (%)-1.0126.6063.1195.92416.692
投入资产回报率 ROIC (%)-1.1317.3413.4716.65719.866

边际利润分析
销售毛利率 (%)80.49183.41485.92988.20291.375
营业利润率 (%)-10.42331.83813.41515.76726.251
息税前利润/营业总收入 (%)-14.67229.9339.74612.82425.922
净利润/营业总收入 (%)-7.42428.86515.02916.67424.448

收益指标分析
经营活动净收益/利润总额(%)-73.67125.10740.37979.26392.377
价值变动净收益/利润总额(%)206.68272.54030.73918.9693.978
营业外收支净额/利润总额(%)-1.3430.3625.8921.235-0.221

偿债能力分析
流动比率 (X)2.8512.9423.2645.4586.560
速动比率 (X)2.6322.8013.0905.1436.197
资产负债率 (%)23.69223.08019.44713.05813.828
带息债务/全部投入资本 (%)12.71212.78210.2951.7080.768
股东权益/带息债务 (%)672.900672.970863.9905,704.06912,635.091
股东权益/负债合计 (%)322.950333.743413.795665.802623.195
利息保障倍数 (X)3.344-14.809-2.161-4.083-95.398

营运能力分析
应收账款周转天数 (天)24.38418.07019.1796.5942.472
存货周转天数 (天)369.534310.428440.314352.322312.971